2018 Spring Conference – Monday, May 7, 2018
The CNS Board is delighted to announce our program for the annual Spring Conference. Our program this year features two expert speakers whose sessions will be both informative and thought-provoking.
8:30am – 9:00am
Registration and Continental Breakfast
9:00am – 12:15pm Session 1
Joanna Jacobus, Ph.D. – Cannabis and the Developing Brain:
What Does the Evidence Say? (additional information below)
12:15pm – 1:00 pm
1:00 pm – 3:15 pm Session 2
Brianne Bettcher, Ph.D. – Mild Cognitive Impairment and Alzheimer’s Disease Dementia:
Biomarkers and Clinical Phenotyping (additional information below)
The PPA Event Center
2105 Decatur Street
Denver, Colorado 80211
Online Registration & Prices
Registration is closed for 2018.
Morning Session – Cannabis and the Developing Brain:
What Does the Evidence Say? – Joanna Jacobus, Ph.D.
This course will focus on the most current research findings on the neurocognitive correlates of adolescent and young adult cannabis use. The course will describe neuropsychological and neuroimaging investigations focused on markers of cognitive status and neural tissue health. Findings will be presented in the context of both cross-sectional and longitudinal studies, studies that have explored the contribution of pre-existing differences, and studies evaluating both acute and longer-term effects on the developing brain.
Dr. Jacobus is an Assistant Professor in the UCSD Department of Psychiatry and licensed Clinical Psychologist in California. Dr. Jacobus completed her predoctoral training in neuropsychology at the SDSU/UCSD Joint Doctoral Program, and her postdoctoral training in the UCSD Department of Psychiatry with specialty in neuroimaging. Her research interests focus on neurocognitive and structural brain changes related to healthy adolescent neurodevelopment and substance use, particularly cannabis misuse. She is working on projects utilizing multimodal neuroimaging approaches to understand the complex relationships between cannabis and alcohol use, structural and functional brain changes, and neurocognitive functioning measured in late adolescence and early adulthood. Dr. Jacobus has over 40 publications in the area of adolescent and young adult substance use. She is part of the NIH-funded Adolescent Brain Cognitive Development (ABCD) research team, the largest long-term study of adolescent brain development and child health in the United States.
Afternoon Session – Mild Cognitive Impairment and Alzheimer’s Disease Dementia:
Biomarkers and Clinical Phenotyping – Brianne Bettcher, Ph.D.
Alzheimer’s disease pathology can present clinically with both typical and atypical phenotypes. Importantly, the development of biomarkers for Alzheimer’s disease (AD)-related pathology has heralded a new era of clinical diagnosis for MCI and AD dementia that presents new opportunities and challenges for the field of neuropsychology. During this talk, we will review the clinical phenotypes associated with AD and the role of biomarkers in case conceptualization and diagnoses.
Dr. Bettcher is an Assistant Professor and neuropsychologist in the Departments of Neurosurgery and Neurology of the University of Colorado School of Medicine. She obtained a PhD from Temple University in Clinical Psychology with a specialization in Neuroscience, and she completed her fellowship at the University of California San Francisco’s Memory and Aging Center. She sees patients clinically at the Memory Disorders Clinic, and specializes in early age of onset and atypical presentations of Alzheimer’s disease. She also directs neuropsychology research at the Rocky Mountain Alzheimer’s Disease Center. Dr. Bettcher’s research laboratory is focused on the neurobiology of aging, and seeks to understand the role of immune system dysfunction in aging and Alzheimer’s disease. Dr. Bettcher uses neuroimaging, cognitive testing, blood markers, and molecular imaging in her research studies to better understand what puts people at risk for Alzheimer’s disease and what protects aging adults from developing Alzheimer’s disease.
For the Morning Session, participants will be able to:
1. Understand the current research on the impact of adolescent and young adult cannabis use on neurocognitive functioning
2. Understand the current research on the impact of adolescent and young adult cannabis use on structural brain integrity
3. Increase competence in identifying unique biological and psychosocial factors that likely contribute to poorer neurocognitive outcomes in cannabis users
For the Afternoon Session, participants will be able to:
1. Identify clinical phenotypes and cognitive presentations of atypical forms of Alzheimer’s disease
2. Understand current conceptualizations and controversies related to MCI and Alzheimer’s Disease dementia diagnoses
3. Understand current biomarker guidelines and the role of multi-modal biomarkers in clinical assessment of MCI and AD dementia
This program is approved for 5.5 hours of continuing education. The University of Denver Graduate School of Professional Psychology (GSPP) is approved by the American Psychological Association to sponsor continuing education for psychologists. GSPP maintains responsibility for this program and its content.
For additional information or any questions, contact
Christopher H. Domen, Ph.D., ABPP-CN email@example.com